[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease

This clinical trial aims to evaluate whether \[¹⁸F\]AlF-OC PET/MRI can characterize and quantify inflammation in carotid atherosclerotic plaques. The study will assess if tracer uptake in culprit and non-culprit carotid arteries, measured by standardized uptake values (SUV), is associated with future cerebrovascular events. Specifically, it will examine whether \[¹⁸F\]AlF-OC uptake predicts the risk of recurrent ipsilateral TIA, amaurosis fugax, stroke, or other vascular complications. Participants will undergo \[¹⁸F\]AlF-OC PET/MRI and will be followed via telephone interviews at 90 days, 1 year, and 3 years after their initial stroke or TIA.

NCT Number	NCT07104487
Lead Sponsor	Universitaire Ziekenhuizen KU Leuven
Conditions	Stroke (CVA) or TIA, Carotid Artery Plaque, Atherosclerosis Cardiovascular Disease, Carotid Arteriosclerosis
Enrollment	24 participants
Start Date	2025-03-18
Primary Completion	2026-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2025-08-11